Abeona Therapeutics Inc. (ABEO) Key Metrics
ABEO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $253.3M
- Enterprise value
- $189.3M
- P/E (TTM)
- —
- Forward P/E
- 18.7
- PEG ratio
- —
- Price / sales
- 9.9
- Price / book
- 2.5 10-yr median 5.2
- EV / EBITDA
- 3.8
- Dividend yield
- —
- Beta
- 1.30
ABEO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsABEO valuation Price multiples at each fiscal year-end price.
ABEO returns How much profit the business earns on the capital it uses.
ABEO per-share figures Results divided by the shares outstanding at year-end.
ABEO financial health Debt, liquidity and how easily interest is covered.
ABEO efficiency & capital use Working capital cycle and where the cash goes.
ABEO valuation history
ABEO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABEO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABEO cash returned to shareholders
ABEO price vs earnings per share
ABEO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $348.5M | $228.6M | $107.1M | — | — | — | — | — | — | — |
| Enterprise value | $182.1M | $154.0M | $60.3M | — | — | — | — | — | — | — |
| P/E ratio | 4.9 | — | — | — | — | — | — | — | — | — |
| Price / sales | 59.9 | — | 30.6 | — | — | — | — | — | — | — |
| Price / book | 2.2 | 5.2 | 7.2 | — | — | — | — | — | — | — |
| EV / sales | 31.3 | — | 17.2 | — | — | — | — | — | — | — |
| EV / EBITDA | 2.3 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 20.4% | −27.9% | −50.6% | — | — | — | — | — | — | — |
| Free cash flow yield | −24.2% | −25.6% | −34.9% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.2% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.27 | $5.57 | $5.01 | $3.08 | $8.50 | $39.25 | $81.75 | $178.50 | $396.25 | $121.25 |
| Per share | ||||||||||
| Revenue per share | $0.09 | $0.00 | $0.16 | — | — | — | — | — | — | — |
| Earnings per share | $1.08 | −$1.55 | −$2.53 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.15 | −$1.36 | −$1.73 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.27 | −$1.42 | −$1.75 | — | — | — | — | — | — | — |
| Cash per share | $2.89 | $2.38 | $2.44 | — | — | — | — | — | — | — |
| Book value per share | $2.41 | $1.07 | $0.69 | — | — | — | — | — | — | — |
| Tangible book value per share | $2.41 | $1.07 | $0.69 | — | — | — | — | — | — | — |
| Capex per share | $0.12 | $0.06 | $0.02 | — | — | — | — | — | — | — |
| Debt per share | $0.38 | $0.56 | $0.25 | — | — | — | — | — | — | — |
| Shares outstanding | 66.1M | 41.0M | 21.4M | — | — | — | — | — | — | — |
| Change in shares outstanding | +61.1% | +92.0% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 70.0% | −216.6% | −260.6% | −114.8% | −117.2% | −60.0% | −48.8% | −37.3% | −20.3% | −26.2% |
| Return on invested capital (ROIC) | — | — | — | — | −617.9% | −175.3% | −89.4% | −85.3% | −75.1% | −61.3% |
| Return on assets (ROA) | 43.3% | −73.7% | −84.5% | −55.2% | −73.6% | −45.0% | −38.4% | −32.1% | −18.9% | −22.9% |
| Return on tangible assets | 32.4% | −58.5% | −84.7% | −61.8% | −108.6% | −71.9% | −49.3% | −57.3% | −19.2% | −31.2% |
| Free cash flow margin | — | — | — | — | — | −363.6% | — | — | — | — |
| Income quality (OCF / net income) | −1.07 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $25.0M | $23.0M | $5.4M | $7.6M | $9.4M | $8.7M | $8.0M | $30.0M | −$3.7M | $0 |
| Cash & short-term investments | $191.4M | $97.7M | $52.2M | $52.1M | $45.0M | $95.0M | $129.3M | $85.0M | $137.8M | $69.1M |
| Net debt | −$166.4M | −$74.7M | −$46.8M | −$44.5M | −$35.6M | −$86.3M | −$121.3M | −$55.0M | −$141.5M | −$69.1M |
| Debt / equity | 0.16 | 0.52 | 0.36 | 0.29 | 0.22 | 0.09 | 0.04 | 0.22 | −0.02 | 0.00 |
| Debt / assets | 0.11 | 0.21 | 0.08 | 0.12 | 0.12 | 0.06 | 0.04 | 0.17 | −0.02 | 0.00 |
| Net debt / EBITDA | −2.12 | — | — | — | — | — | — | — | — | — |
| Current ratio | 6.93 | 6.08 | 4.15 | 6.83 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Quick ratio | 6.74 | 6.08 | 4.15 | 6.78 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Interest coverage | -23.9 | -15.3 | -112.8 | -69.2 | -24.6 | -19.8 | -192.7 | — | — | — |
| Working capital | $175.3M | $84.3M | $42.3M | $45.3M | $39.7M | $55.8M | $93.7M | $68.5M | $135.0M | $61.1M |
| Invested capital | −$7.2M | −$30.6M | −$32.0M | −$17.8M | $6.7M | $16.2M | $57.1M | $79.1M | $28.6M | $30.0M |
| Tangible asset value | $159.2M | $44.0M | $14.8M | $26.8M | $41.0M | $68.6M | $109.8M | $58.5M | $133.7M | $58.2M |
| Net current asset value | $144.6M | $36.0M | $6.6M | $15.6M | $19.1M | $49.1M | $87.4M | $48.5M | $131.9M | $57.5M |
| Graham number | $7.64 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | $2.10 | $0.83 | $0.23 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | $182,000 | $26.2M | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 137.0% | — | 9.5% | 9.2% | 138.4% | 13.4% | — | 650.2% | 102.7% | 58.4% |
| Capex / depreciation | 2.24 | 0.84 | 0.10 | 0.03 | 0.93 | 0.24 | 0.75 | 8.26 | 1.16 | 0.63 |
| Stock-based compensation / revenue | 185.2% | — | 136.2% | 215.8% | 297.2% | 81.9% | — | 295.7% | 706.8% | 543.2% |
| R&D / revenue | 460.7% | — | 888.3% | 2,048.4% | 1,290.9% | 301.4% | — | 1,290.8% | 2,029.7% | 1,198.5% |
| SG&A / revenue | 1,117.4% | — | 543.0% | 1,220.4% | 721.5% | 237.8% | — | 670.6% | 1,307.4% | 1,494.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 262.4 | — | 137.2 | 411.5 | 182.5 | 0.0 | — | 11.4 | 50.4 | 49.1 |
| Days of inventory on hand | 654.4 | — | — | 137.1 | 0.0 | — | — | 0.0 | — | — |
| Days payables outstanding | 1,349.7 | 332.7 | 417.2 | 2,488.5 | 42.5 | 51.2 | 37.1 | 37.7 | 59.9 | 78.3 |
| Cash conversion cycle (days) | -433.0 | — | -280.0 | -1,939.9 | 140.0 | -51.2 | — | -26.3 | -9.5 | -29.2 |
| Receivables turnover | 1.39 | 0.00 | 2.66 | 0.89 | 2.00 | — | 0.00 | 31.89 | 7.25 | 7.44 |
| Payables turnover | 0.27 | 1.10 | 0.87 | 0.15 | 8.59 | 7.13 | 9.83 | 9.67 | 6.09 | 4.66 |
| Inventory turnover | 0.56 | — | — | 2.66 | 38,726,000.00 | — | — | 77,396,000.00 | — | — |
| Asset turnover | 0.04 | 0.00 | 0.05 | 0.02 | 0.03 | 0.05 | 0.00 | 0.02 | 0.01 | 0.01 |
| Average receivables | $4.2M | $2.0M | $1.3M | $1.6M | $1.5M | $0 | $40,500 | $94,000 | $115,500 | $119,500 |
| Average payables | $5.7M | $2.6M | $1.8M | $3.1M | $4.5M | $4.2M | $4.9M | $4.0M | $2.8M | $2.3M |
| Average inventory | $2.7M | $0 | — | $169,000 | $1 | — | — | $0 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 22.5% | 30.7% | 43.3% | 20.4% | 36.8% |
Computed from ABEO's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ABEO valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Abeona Therapeutics traded at 4.9 times earnings. Abeona Therapeutics earned a return on equity of 70.0% in fiscal 2025. It ended the year with $25.0 million of debt and $191.4 million in cash and short-term investments, a net cash position of $166.4 million.
See the ABEO income statement, the ABEO chart for price history, or the ABEO stock overview for the latest quote and news.
ABEO key metrics FAQ
What is Abeona Therapeutics's P/E ratio?
Abeona Therapeutics traded at 4.9 times earnings at the end of fiscal 2025.
What is Abeona Therapeutics's EV/EBITDA?
Abeona Therapeutics's enterprise value was 2.3 times EBITDA at the end of fiscal 2025 (enterprise value $182.1 million, EBITDA $78.6 million); the current EV/EBITDA is 3.8.
What is Abeona Therapeutics's return on equity?
Abeona Therapeutics's return on equity (ROE) was 70.0% in fiscal 2025: net income of $71.2 million on average shareholders' equity of $101.6 million.
How much debt does Abeona Therapeutics have?
Abeona Therapeutics had total debt of $25.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.16 and more cash than debt.
What is Abeona Therapeutics's free cash flow yield?
Abeona Therapeutics generated -$84.3 million of free cash flow in fiscal 2025, a free cash flow yield of −24.2% on its market value at year-end ($348.5 million).
What is Abeona Therapeutics's current ratio?
Abeona Therapeutics's current ratio was 6.93 at the end of fiscal 2025: current assets were 6.93 times current liabilities.